the absolute best. >> that was the best gift we've gotten ever in the history of "fast money." >> going to miss you. >> we're going to miss you. >> she's awesome. >> thank you, amelia. >> brig. >> thank you for watching "fast money." good luck, amelia. "mad money" with jim cramer starts right now. my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now. hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends. i'm just trying to make you a little money. my job not just to entertain but context, teach, educate. call 1-800-743-cnbc. tweet me @jimcramer. everyone knows the ascent of the mega caps, the nation state companies i call them, has created a disparity between the

trillionaire companies. of course they've gained that because of explosive earnings. not just multiple expansion meaning people pay more for the same numbers over and over again until they collapse under their own weight. the megacaps define the market on a daily basis. dow advanced, nasdaq shed .24%. i know they're one of the key reasons why the s&p 500 is knocking on the door of an amazing milestone which is the s&p 5,000. but we're not passive observers here on "mad money," right? this is a teaching show. not a history lesson on how apple or nvidia or microsoft got here. we're not going to say forget this market, you missed it. i hear a lot of people saying that. or it's broken. okay, fine. frankly i like the megacaps on a pullback like you just got in apple where my attitude remains own it, don't trade it. every day the stock 345rk9 can give you opportunities to make good money. perhaps much more than you'd make by parking your cash in certificates of deposit, which on days like today feels like a

velvet prison for your money. you can get 5% risk-free for doing nothing. okay, i'm not going to denigrate that. but how about this? arm holdings, this morning rallied nearly 48%. in the wake of a tremendous quarter. one we actually totally saw coming. arm semiconductor designs can be found in pretty much every kind of device, especially smartphones. and they've got a great partnership with, yes, nvidia. today the stock soared like it caught a takeover bid because the quarter was so good. not to mention it was way to cheap. the most sophisticated smartphones, data center, generative ai. more on that later in the show when we take a deep dive into arm's quarter and explain what to do if you owned it after today's move. you might think arm's extremely rare. and it is extraordinary. but you know what? there's another characteristic to m this market that doesn't get enough air time and i'm going to change that right now. i'm not just talking about the

huge winners like eli lilly or amazon. these days there are so many solid gains, 10% or more, created daily around here. it's pretty astounding in itself. i ran a screen of the s&p 1500 to see how many stocks have given a 10% gain just since tuesday's close. why does this matter? because even if you take profits on the 10% gain and pay the taxes you're going to beat what you would have earned in a year of leaving your cash on the sidelines. i don't denigrate anything that gives you a sizable return. but can you at least admit you might be missing out on some huge gains if you steer clear of the stock market? notable gains from the small sample so you can see how broad the rally really is despite what you may hear in the press, the chattering heads, whatever. you have this regenix which is a drug company that revealed it might have something against duchesne muscular dystrophy. it's a terrible disease. very rare. meaning they can charge very high prices for any treatment. that stock vaulted nearly 25% in

two days in response to the news. second, 20% gain, xpo a trucker of all things. it will expand taking advantage of the bankruptcy of competitor and has a terrific increase in cargo per truck year over year. the trigger leading to the monster move a much better than expected quarter. and cirrus logic up 19%. cirrus logic is responsible for the sound in your iphone. right here. and much to the chagrin of the apple bears these guys reported an astounding quarter thanks to apple cellphone orders. next advanced drainage systems up nearly 18%. infrastructure play. and there's so much infrastructure in this country right now you'll have a hard time not making money in the sector. after that get this, it's ralph lauren. the classic apparel play, which rallied nearly 17% today on an awesome quarter. with great sales including lots of business in china. that's a stupendous gain, one that we've been saying should have happened after the last quarter. that was a great one. but it happened. then there's an outfit called monolith power. that's a gain of 16%.

chip company involved in artificial intelligence and reported a wildly strong quarter. i want you to consider it to be riding the coattails of nvidia, arm and broadcom. next is old fave enphase energy. solar power company that called the bottom on solar sales earlier this week causing the stock to rally 16%, taking up solar edge and generac along with it. quinn street, insurance marketing specialist, jumped 14.5% on a spectacular quarter. and rounding it all out is sonos, up 10.5%. sophisticated sound systems for your home and it's part of a large cohort of home improvement stocks that are working. and here i'm thinking about companies like trex that just reported a big quarter. didn't we say we should be buying the stock of home depot? if those are too obscure let's talk larger names. walt disney jumped 11.5% today on a terrific turnaround quarter

fueled by dividend boost. after years of underperformance that have really hurt me. wynn resorts. another charitable trust name. vaulted 6.3% today alone as it's returned to hypergrowth move in both vegas and in macaw is finally happening. numbers were so amazing we added to our position for the charitable trust telling club members in the morning meeting that wynn's business is much boater now at this point than it was substantially higher a few years ago. another club name palo alto networks rallied again up 7.5% since last tuesday and with this long-term holding jumps every time any other company in the cybersecurity cohort moves up. this time it was fortinet, not a great company. what does this list tell you about this market? it's simple. we didn't get to these new highs just through the megacaps. we got there through moves like the one we just talked about since last tuesday. all this might be happening because the market remains a scorned animal, a lowly skunk in a 5% cd block party.

all i ask is that at least you consider participating in stocks. bottom line, there's just too much money being made in excess of what you can get from cds, even after taxes. and stocks like these are the 10% solution to those passive risk-free gains. except those rallies happened overnight. the risk-free 5% takes an entire year, with zero possibilities of any additional upside. let's take calls. let's go to tony in florida. tony. >> caller: hey, jim. i just want to give your team a boo-yah. i know we keep on saying it but you do have one of the best teams there. >> the team is great. i was with the guys last night, a whole bunch of us go out for our birthdays. and i was just saying the team makes it so i can keep working. the team. so thank you for recognizing that. let's go. >> caller: yeah. this stock, i have some eli lilly but i wanted another health care stock to go with it. and basically it kept me and my wife out of the hospital because we did get covid once.

i saw the interview you had with him and if he's going to try to beat cancer what do you think about a position in pfizer? >> pfizer's really interesting. you get paid 6% to wait to see how good seagen is. and seagen's got some near miraculous possibilities for some of the worst cancers in the world. so i am with dr. bourla. i'll take the 6% and see what seagen gets me. there's too much money being made in excess of what you can get from cds and stocks like these are the solution, frankly, to just getting the passive risk-free games that have no more upside other than what you buy from the beginning. on "mad money" tonight ge healthcare had a healthy profit forecast for 2024, which has piqued my interest, and i'm hearing more about what's working for the charitable trust name. i sit down with the ceo. then that big hoff in arm that i mentioned that was a thing of beauty wasn't it? but does the long-term opportunity remain after today's huge jump higher? i'll give you my take. and then vertex pharmaceuticals, talk about pfizer, how about vertex? it fell after earnings this

week. so are investors getting a buying opportunity, which has been the case every time it's fallen? i'm going to sit down with the ceo and get the latest. so stay with cramer. >> announcer: don't miss a second of "mad money." follow @jimcramer on x. have a question? tweet cramer. #madmentions. send jim an e-mail to madmoney@cnbc.com. or give us a call at 1-800-743-cnbc. miss something? head to madmoney.cnbc.com. ♪ ♪ every day, businesses everywhere are asking: is it possible? with comcast business... it is. is it possible to help keep our online platform safe from cyberthreats? absolutely. can we provide health care virtually anywhere? we can help with that. is it possible to use predictive monitoring to address operations issues?

we can help with that, too. with the advanced connectivity and intelligence of global secure networking from comcast business. it's not just possible. it's happening. that first time you take a step back. i made that. with your very own online store. i sold that. and you can manage it all in one place. i built this. and it was easy, with a partner that puts you first. godaddy.

is it possible to count on my internet with a partner like my customers count on me? it is with comcast business. keeping you up and running with 99.9% network reliability. and security that helps outsmart threats to your data. moaire dida twoo? your data, too. there's even round-the- clock customer support. so you can be there for your customers. hey billy, how you doin? with comcast business, reliability isn't just possible. thanks. it's happening. get started for $49.99 a month. plus, ask how to get up to a $1000 prepaid card with a qualifying internet package. don't wait, call and switch today!

i said from the outset we've witnessed some monster moves to the upside this week. one of the biggest winners for the charitable trust came from a company called ge healthcare

technologies, a medical device business that was spun out of general electric a little over a year ago. after trading sideways for a couple months ge healthcare came out on tuesday and reported a magnificent quarter. 11-cent earnings beat off a $1.07 basis. higher than expected stales for three out of four divisions organic growth of 5%. even better management gave a very strong full-year forecast which is why the stock jumped 12% on tuesday in response. and i think this is just the beginning of the move. hence why we own a huge amount of it for the trust, something you'd know all about if you belonged to the cnbc investing club. but let's check in with peter arduini, the president and ceo of ge healthcare technologies to get a better sense of these numbers. peter, welcome back to "mad money" and congratulations on a great quarter. >> hey, jim. good to see zblup you. >> good to see you. unbelievable view. first year as a public company. you basically predicted many good things. and sure enough, positive organic growth you just announced. gained market share.

stock blew up. can you give us, what have you been able to doin your first year that maybe you couldn't do at ge? because things are really coming together for this company. >> yeah, thanks, jim. it's always great to be on your show. a lot of it is the premise of three separate companies out of general electric. focus is a lot. we have a very focused board. we have people coming to us that really are dedicated to health care. and then we've been able to free up our own balance sheet to invest across the company. i mean, those are really at the core of it. >> well, to me you've also been able to embrace artificial intelligence in a way perhaps you might not have been able to if you were still in a larger conglomerate. why don't you tell us some of the things you're doing because to me this is the real value added you're bringing right now to doctors, to patients, to hospitals at this very moment. >> yeah, jim. so to that balance sheet point, to be able to do double-digit investments in r&d, which we did this year, while still driving up our ebit rates, it is a lot going into digital and ai.

and to your point there's a couple different areas of it. the first is ai inside, if you will. so our mris, our cts, our ultrasound are all being greatly enhanced with ai algorithms that either help make the image better, so better diagnosis, better productivity for the user, or actually making it so new users can use the device. as an example, handheld ultrasound. and in all those cases customers are willing to pay more, bringing up better margins. the second area is you know health care's full of all types of data. the challenge is it's not used that much. so a big part is actually how do you format data for decision-making. and we have products like command center, which is actually -- helps a hospital run their system more effectively. and then the last piece which we're assembling now and will evolve in the next few years is what's called multimodal data integration. your genomics information, your pathology information, your image data all together on one pane of glass. and a given algorithm or foundational model that can help

decipher through that data and help your clinician move you in the right direction. so those are all the kind of exciting things that we're investing in right now, jim. >> peter, you're in a dogfight. there are others in your category. i think these are real differentiators that create a moat for you. how is business in general, both in the u.s., overseas and china? because all these things play a role in how you were able to have such a nice upside surprise. >> yeah, look, we've obviously had a very good first year. we put up 8% organic growth with all the things that are going on when you're coming out as a separate public company. but again, in the one word focus we were able to enable that for the team. and i think really with our investments in r&d this year we've had a really nice pipeline of 40 new product introductions, all of those products coming out with better gross margins than their predicate product. and so those things start adding up. they're a flywheel effect. i would say if you looked at the previous years in '22 and early

'23 there was questions with rates going up and hospital p & ls maybe not being as strong as they had been in the past. we started to see in the second half of this year via discussions with our customers and surveys that their p & ls were strengthening and they're having more confidence to invest in capital. so we were the beneficiary of that. we had a nice strong q3. and then the great part about that is that parlays into '24. so i start '24, our team does, with over $19 billion backlog that really sets us up well. outside the united states i think europe is moving along well. we've got a lot of growth in southeast asia. china's an interesting one. it's a country of a billion four people. 400 million have good health care. about a billion don't. so there are plenty of opportunities to grow. but i think this year it's going to be a little bit more cautious as we move through the year. we had a tremendous year in '23. our first half was over 20% growth. and so as i said on the call we're expecting first half to be

negative growth and then resume the positive growth in the second half. that's for china. but overall we're delighted with the macro i'd say relative to our space. >> i think the analysts are finally catching up to that. i felt that you and i were the two who believed and now they're all scrambling to get ahead of it. now, i was -- >> you were a big supporter through all this. so thank you. >> i hate to say it but i've been a big consumer of it. now, i was the chief spokesperson for the american brain foundation and we know that eli lilly is about to come out this quarter and get the word from the fda about alzheimer's. and the people with the brain foundation told me over and over again the system cannot afford everyone just saying listen, i want this treatment. so you're going to probably need mris and know family history, and if the mri doesn't show a problem you're not going to get these alzheimer's drugs. how important will ge healthcare be to actually save the system? because we know the system goes bankrupt if everybody decides that they don't want to have -- they're going to stop

alzheimer's in its tracks. even if they don't need to. >> i think the first part is, jim, is you and i talked about the fact these new drugs are coming out is a big opportunity for patients in a world where there hasn't been many options. so we start with that. and then secondly as i've mentioned before, we're a facilitator to help the right patients get the right therapies. and it starts with our pet yt and the actual imaging agents, a product called visamel that helps quantify the am'llyl beta plaque. it's going to be pretty clear who should actually move on to the drug. and as you know we play a role after each administration with an mri to make sure that any potential side effects are managed appropriately. and so that the patient can move forward. we're working with health systems as they're thinking of their strategies of o'how they want to work through p this. we would expect to see this i picking up in the second half of

'24. >> your consumer business, you have contrast agents, you have things that make it like -- this is something the analysts are just discovering. regular streams of revenue coming from not just the har hardware. >> yeah, exactly. broadly over 45% of our revenue is reoccurring. a lot of that is big multiyear service contracts. but to your point, in our pdx, pharmaceutical diagnostic business, we have contrast agents that are used in all types of vascular or heart procedures. then this whole area of moll eblg lar imaging. and again, this is just really beginning to take off. the product i mentioned for alzheimer's would fit into that zone. but as you get into other oncology imaging and cardiology imaging, those will be really interesting molecules to drive our rowth. and to your point they are reoccurring assets. >> the story is terrific. you delivered entirely. one of the biggest gains that i've seen of a newly public company. of course overshadowed today because of arm holdings. i'll take what you did any day of the week. peter arduini is the president and ceo of ge healthcare.

a charitable trust name. thank you so much, peter. >> thanks, jim. appreciate being on. >> i know it's hard to find inexpensive stocks. believe it or not, even after the move here this stock is much less expensive than any of its peers. ge healthcare. "mad money" will be back after the break. >> announcer: coming up, arm is hammering. cramer takes you behind the stock's rocket-fueled day. next.

this thing, it's making me get an ice bath again. what do you mean? these straps are mind-blowing! they collect hundreds of data points like hrv and rem sleep, so you know all you need for recovery. and you are? i'm an investor...in invesco qqq, a fund that gives me access to... nasdaq 100 innovations like... wearable training optimization tech.

uh, how long are you... i'm done. i'm okay. every day, more dog people, and more vets are deciding it's time for a fresh approach to pet food. they're quitting the kibble. and kicking the cans. and feeding their dogs dog food that's actually well, food. developed with vets. made from real meat and veggies. portioned for your dog. and delivered right to your door. it's smarter, healthier pet food. get 50% off your first box at thefarmersdog.com/realfood

we need to talk about the spectacular run in cramer fave arm holdings. with semiconductor design powerhouse saw its stock soar 48%. 48% in response to just a tremendous quarter. with that kind of move you'd think they caught a takeover bid. but no, it's just that the numbers are really that good. i pounded the table on arm holdings from the moment it came public again last september. giving my blessing to buy it in the low 60s then telling you to back up the truck if we ever got a pullback to the 50s. >> buy buy buy! >> the stock swooned with the broader market even dipping to the high 40s in late october. arm even got clobbered after reporting its previous quarter back in november even though the results were terrific because management came in with conservative guidance. we had ceo rene hobbs on the show that very night and he made a very compelling case for his company. i hope you listen because after today's miraculous run it's up to just under $114. in fact, there was a tell in

arm's first earnings report out of the gate and that was a clue the business was about to improve dramatically. they have two types of revenue. what they get from royalties and what they get from licensing. arm designs semiconductor architectures that other companies use to sell chips. whenever they sell chips they pay arm a royalty. but before that whenever they choose to use arm's designs they have to pay an up-front fee for licensing. the royalty revenue base is enormous because the low power chip designs are in everything. the up-front licensing numbers give you a much better sense of where the business is headed in your future. and when arm reported in.95 their licensing revenue was up a stunning 6% year over year, massively better than expected, in other words we knew their customers were ramping up investments in new chips using arm's processor designs. when the brilliant haas came on the show that night talked about a refresh cycle in all devices because today's computing requirements are so much higher than older chips can support.

i want you to fast forward to three months later. when arm holdings reported last night it posted a monster revenue beat, 14% growth year over year. royalty revenue was up 11%. a major improvement from last quarter. and their license revenue jumped 18%. also substantially better than expected. arm explained that bookings are on fire because of the need for more powerful chips to support, yes, ai. the earnings lines look so good too, margins better than expected. company delivered a 4 cent earnings beat. this time arm's guidance didn't disappoint. management raised thissar full year guidance substantially, raising by more than 5%. taking their earnings guidance from the dollar to dollar ten range all the way up to dollar, dollar 24 range, easily topping the dollar per share wall street was looking for. on top of that much better than expected. what's behind this? arm's the dominant player in chip designs for the smartphone factor market. smartphones are growing again. customers are increasing using arm's latest cpu design called the arm v-9, which has a royalty rate that's at least double what

they're getting for the previous v. in the previous quarter they were getting 10% for the chip architecture but now it's been moved up to 15%. and they're not just doing well in smartphones. they also saw strength in the data center, automated chips and other end markets, internet of things. how about the growth in licensing revenue that comes from new business? again, arm says that's all about the need for new hardware to power, and i quote, all things ai, end quote. arm's powerful yet energy-efficient designs are the best processor solutions for these new products. as haas explained when he joined us on "squawk on the street" this morning, arm has an edge because it cut its teeth designing chips for battery-operated devices, especially phones, where energy efficiency is the whole ball game. listen to this. >> you've got very power-efficient products moving in a world where power efficiency matters not only in a smartphone but it matters in an ev and it absolutely matters in a data center when you're trying to run these huge ai algorithms. >> that in a nutshell is the story behind arm's amazing

numbers. but what the heck are supposed to do with the stock now that it ran up 48% in a single day? keep in mind this is not a small company. arm had a market capitalization of 80 billion yesterday. now it's 117 billion. again i really hope you listened when i pounded the table op this one repeatedly. if you bought arm holdings on my recommendation, you've got to do what i call a little -- you've got to take something off the table here. go buy a proverbial sweater. stock's doubled in a matter of months. it's pure greed not to ring the register. you can sell half. play to the house -- with the house's money. that's always admirable. what makes me a tad concerned with the stock with this greet company going forward. look, long term i love arm holdings. short term soft bank still owns a percent of the company and they're locked up -- soon or later they're going to want to sell their position. a huge chunk owned by nvidia, apple, google, intel. they aren't likely to sell anytime soon. but one reason the stock could rally 48% today is there are so

few shares that actually trade of the total number of shares outstanding. problem is the lockup is not ironclad. it's not a law. it's an agreement between the company coming public and its underwriters. there are ways for lockups to be broken early especially when the stock catches fire out of the gate like this one did. the lockup ends in barely more than a month. i have no idea whether soft bank will do much selling but i think they'd be crazy not to ring some of the register given how much the stock's run if they have an ounce of responsibility they will do some selling. if you don't own arm holdings how about this? wait for the stock to pull back on the lockup expiration. it's really about the supply and the demand of the stock, not the company's products. i am not worried at all about the power of the company's products or its execution, not one bit. unwavering. bottom line, i've never gone on to root against one of my favorite stocks going higher, especially when i've recommended it so many times. but even though arm holdings reported great numbers and a great forecast today a 48% move i'm calling it eye-popping, if there were more shares trading it probably wouldn't have run

like it did. so please, do the responsible thing. take a little off the table. although you should do it gradually because this market can extend supportive moves. if you bought arm in the 50s on my recommendation sell some here to make me feel better and then make you feel incredibly profitable. that's the best way to play. joe in florida. joe. >> caller: jim. hi, jim. boo-yah. >> boo-yah, joe. >> caller: i'm a long-time listener and a avid club member. my question pertains to a cybersecurity company that sells infrastructure software. they have a market cap of 77 bil billion. they play in a competitive environment with the likes of microsoft, palo alto networks and sentinel one. with my current holdings should i buy more shares, sell a portion or hold? my stock is crowdstrike. >> crowdstrike's amazing. george kirsch is incredible. the stock did hit a 52-week high today. i am not going to tell someone to start buying even more stock

at a 52-week high because as you know from the club we don't do that. we have to wait. that said, crowdstrike is a fantastic company, as is palo alto. i could not put the other one in the same sentence as those two. now let's go to david in florida. david. >> caller: big boo-yah to ya, jim. >> you bet. >> caller: i'm calling in regard to a stock i started buying incrementally in 2016. i have taken profit. i got my initial investment back. and right now i'm kind of wondering if it's -- continue buying holding or whatever. and the stock is box. box. >> i just don't think it's proprietary enough at this point. i think there are so many other great tech companies. look, aaron levy's terrific. he's a great ceo. but i've got to tell you, i think go for more proprietary and go for more semiconductor and i think you will do better. i think when it comes to arm you should do the responsible thing and maybe take something off the table because you probably have more than a double if you bought

it in the 50s. if you sell some, play with the house's money. much more "mad money" ahead. biotech companies tend to release a drug hope to be acquired or maybe combine with another outfit. vertex bucks the trend as a stand-alone company. the company continues to innovate. it is one fabulous story. we'll check in with the ceo. and artificial intelligence is missing one thing. i'll reveal what it is. it might be a little surprise. and all your calls rapid-fire in tonight's edition of the "lightning round." so stay with cramer. at morgan stanley, old school hard work meets bold new thinking. to help you see untapped possibilities and relentlessly work with you to make them real.

[♪♪] your skin is ever-changing, take care of it with gold bond's healing formulations of 7 moisturizers and 3 vitamins. for all your skins, gold bond. awkward question... is there going to be anything... -left over? -yeah. oh, absolutely. (inner monologue) my kids don't know what they want. you know who knows what she wants? me! with empower, we get all of our financial questions answered. so you don't have to worry. empower. what's next.

shopify's point of sale system helps you sell at every stage of your business. with fast and secure payment. card readers you can rely on. and one place to manage it all. whatever the stage, businesses that grow grow with shopify. there are some things that work better together. like your workplace benefits and retirement savings. voya provides tools that help you make the right investment and benefit choices. so you can reach today's financial goals. and look forward to a more confident future. voya, well planned, well invested, well protected.

a couple months ago i

pounded the table on vertex pharmaceuticals. i've been a fan of this cannot for their cystic fibrosis franchise far and away the best in the space. now it's gone beyond with a new drug for sickle cell disease and an incredibly promising non-addictive drug for pain. and that's why i want to take a closer look with dr. reshma kewalramani. she's the president and ceo of vertex pharmaceuticals who joins us now. welcome to "mad money." >> good afternoon, jim. nice to see you. >> it is a great treat to have you on because i have long admired your company as you know because i have multiple times over the years said people should own vertex. but what i want you first, if you don't mind, is to talk about what the standard of care was for cystic fibrosis and what you've done for this community that is just -- it's heartbreaking but you made it better. >> jim, i was in medical school at the time that patients had

access to the standard of care before vertex came along. i was a practicing physician before vertex's medicines came along. and basically it was lots of cf patients in hospital having pulmonary exacerbations, not able to breathe, not able to live their life. and then in 2012 vertex came along with its first medicine. many people called it a miracle pill. and since that time we've steadily invested and innovated, and now we're at the point where 90% of people with cystic fibrosis have a medicine that can treat the underlying cause of their disease. it is remarkable. >> and you continue to make it better. people should know. i know some people say these are just incremental changes. i think they're far more than that. you're making people's lives better. you're not just resting on the 2012 laurels. >> you know, that is exactly right. when you think about cystic phonerosis, the actual underlying cause of the disease is known. we know the genetic

underpinnings of this disease, and that's why we keep innovating and serially innovating. if it is possible to do better than the last drug we brought forward, which is a wonderful medicine, we're determined to be the ones who do it. and the goal here, jim, to be clear, is to bring our cystic fibrosis patients to the same level of health as you and me. that's the real goal here. >> boy, well, if only people -- those of us who know what it was like before that, that's an amazing statement. now, one thing is for certain, which is that you have i sense an awareness problem. like so many good drugs, the doctors either don't know about it or the patients don't know about it. how do we get the word out so that younger patients know this? >> you know, in the cf community, jim, we're really very fortunate. the community has a lot of advocacy and agency built in. this is a disease that runs in

families. patients know that they have siblings or that they have family members with this disease, and children are born with this. and for that reason they're in the health care system. they're looking for the best medicine. and they're looking to get to a place where they're healthy and living their lives. so i would say that the community's very aware of vertex. we have kids come over when they see the big vertex sign in boston when they're visiting to come and say hello to our scientists. >> well, that's thfantastic. one of the reasons i've liked your stock even more of late. as your c.o.o. said in the excellent call earlier this week you guys are now in a position where you're entering a new era of commercial diversification which even though your market cap is big it to me seems very small versus what you can accomplish. why don't you talk about sickle cell and then we'll get to pain. >> sure thing. so sickle cell disease is very interesting because we knew the genetic underpinnings of this disease about 30 years before we

mound the genetic underpinnings of cystic fibrosis. and what that means is this disease hasn't had any real innovation for a very long time. it's a disease that affects black and brown people, and it's a disease where blood cells are misshapen and cause an enormous amount of pain in patients who have sickle cell disease. people describe the pain as a mack truck running them up and down and up and down again. and the sister disease is beta falcemia where you require constant blood transfusions. and what we've done with our partners at crispr therapeutics is a one-time precise durable gene edit. this is based on crispr cast 9 which some have called molecular scissors. it's a one-time therapy, and we expect it to have a potentially lifetime of benefit. >> okay, now, i don't want to get people's hopes up too much, but what you're doing with pain could change the country if not the world. and i've got to give you some

time to talk about it because if it works we can get rid of drugs that we know are addictive and harmful and introduce a drug that may actually be the holy grail, what we need for those of us who suffer from constant pain. >> you're very right, jim. i want to be very thoughtful about how we talk about this pain medicine. it is a very important scientific and medical breakthrough. to give you a sense of why i say that, in human beings we know that there are families, kindreds, who have mutations in what is called the nav 1.8 channel or the nav 1.7 channel. if you have a mutation in the nav 1.7 channel, there's a pakistani family of firewalkers, they literally walk on hot coals but feel no pain. they're normal in every other way. people who have genetic mutations of nav 1.8, if they have an overexpression, they

have a constant sense of tingling and burning sensation. these were the insights that our scientists took, and these are the insights that have led to the medicine or the potential medicine called vx 548 for which we recently delivered positive phase 3 results. that was the results from last week. in december we had results in chronic neuropathic pain. same molecule, vx-548. >> doctor, was this is such an important issue, can you tell us what you would like to accomplish versus the current standard of care for pain. >> the kucurrent standard of ca with acute pain is safe and well-tolerated medicines but of low efficacy on the one hand and on the other hand we have opioids which are efficacious but of course come with concerning risks including very importantly addiction potential. and what we're trying to do is develop our medicine, which has now passed the last stage of

clinical trials, so that it can fill that therapeutic gap between low efficacy but safe and tolerable and opioids. and what i see with vx-548 is a medicine that has therapeutic efficacy but the kind of safety and tolerability profile we've been waiting for. and because it only works in the peripheral nervous system it doesn't have addiction potential because the way you have addiction is through a central nervous system phenomenon. >> well, look, thank you so much for the work that you're doing and your team, and we just have to hope that this works because it will change our country. vertex will change our country. thank you so much for being on. >> thank you. >> absolutely. that is dr. reshma qkewalramani. she is the president and ceo of vertex pharmaceuticals. it is a terrific company and a great stock. "mad money's" back after the break. >> announcer: coming up, pop open those umbrellas and tee up your toughest questions.

cramer takes on all comers in the "lightning round." next.

switch to shopify and sell smarter at every stage of your business. take full control of your brand with your own custom store. scale faster with tools that let you manage every sale from every channel. and sell more with the best converting checkout on the planet. a lot more. take your business to the next stage when you switch

to shopify. my name's cody archie. and i'm erica. cody: and we're first generation ranchers from central texas. erica: and because of tiktok, we're able to show people from all over the world where their food and fiber come from. cody: we have dorper sheep and we have beef cattle for the sole purpose of going into the food chain. we use tiktok as a tool to inform people of what we do and why we do it. there's just a plethora of knowledge and of information swapping going on there. tiktok is helping us protect this way of life for future generations.

at morgan stanley, old school hard work meets bold new thinking. to help you see untapped possibilities and relentlessly work with you to make them real. it is time! it's time for the "lightning round" on cramer's "mad money." play until this sound and then the "lightning round's" over. are you ready skee-daddy? oh, yes. we're going to start with brian in utah. brian! >> caller: jimmy chill. from park city, utah. and i have been following you since the kudlow days, my

friend. >> oh, my god. i had a full head of hair back then. that was something, huh? actually, i still have it. i just cut it really short like everybody else does. >> caller: that was really something too. hey, listen, with such a strong u.s. economy what do you think of the leveraged loan space via clo equity funds like oxford lane -- >> the problem, brian, is if we don't know whether they're good -- we don't know if they're any good at credit. and we don't know what they own. i like the concept. and this n. that sense i think i would look at blackstone because they really know how to do it. let's go to michael in colorado. michael. >> caller: hey, jim. shout out from the land of primetime deion sanders and the colorado buffs. >> oh, if i could ever get to the university of colorado i'm telling you, i'd turn the whole world upside down. yes. and that would be my goal, to get the university of colorado. >> caller: jim, my portfolio by

allocating 25% on international stocks. two weeks ago i asked you about ferrari. today i'd like to get your thoughts on mer kato libre. >> i never once abandoned it. those people are incredibly stock. that is the stock to own if you have to own a stock in lat am. >> caller: thanks for taking my call. i love your show. a boo-yah from yukon, oklahoma. the question is mcmoran. >> i think it can go up a couple points once the chinese start manipulating their market but that's all. you have to go higher quality. now i want to go to mark in virginia. mark. >> caller: howdy, professor cramer. you are the king of invest-atainment. i've been following you -- >> i embrace that.

they learn. other people say it's a trading show. yeah, trade apple, trade nvidia. what do people want from me in how can i help? >> caller: well, i've been following you and just the idea of getting people educated, to get in the stock market, do a little picking and do a little trading mostly buy and hold those golden stocks. >> yes! >> caller: i've been looking at some of the news on the weight loss drugs, et cetera, et cetera. one beneficiary that i have in my portfolio just by luck is being touted as the ozempic-based solution and that would be abbvie. >> that's botox and people who take those drugs can get -- their faces get too thin because you lose your weight, it goes in some places of your body you lose more weight than others. and abbvie's making a fortune off it quite frankly. and abbvie has a lot of other good drugs. and it's a very good company. that's a great call, by the way. great call. let's go to jerry in north

carolina. jer. >> caller: hey, there's not much press coverage on aurora innovation. they're set to launch their driverless trucks in texas this year. what's your take on the company? >> i actually know the company. my problem is that i don't recommend companies that lose a lot of money because then what happens is they turn out to be charging stations or something. everybody criticizes me. and i have really thin skin. let's go to jonathan in pennsylvania. jonathan! >> caller: boo-yah, jim. i just renewed my investment club membership for two years. >> thank you. thank you, partner. i really appreciate that. that's what i want. i want people to be educated with me. how can i help? >> caller: thank you and everyone there. we learn so much from the club. the perfect amount of content for us. not too much -- >> thank you. that's what i was telling my buddy robbie last night. i said listen, we're not going to overwhelm you with research but we'll give you the straight stuff. thank you. thank you. what's up? >> caller: yeah. and one of the many things i've learned is the rule of 40 from you guys. i've got a stock i'm asking about that the rule of 40 is actually in the low 50s. what do you think about united

therapeutics? thanks, jim. >> i have not looked at united therapeutics in too long a time, and i'm going to have to study it and then come back with a considered response. and thank you for your kind words. and that, ladies and gentlemen, is the conclusion of the "lightning round"! >> announcer: coming up, ai has the scarecrow covered. but cramer's looking out for the tin man. next. ameritrade is now part of schwab. bringing you an elevated experience, tailor-made for trader minds. go deeper with thinkorswim: our award-wining trading platforms. unlock support from the schwab trade desk, our team of passionate traders who live and breathe trading.

and sharpen your skills with an immersive online education crafted just for traders. all so you can trade brilliantly. [busy hospital background sounds] this healthcare network uses crowdstrike to defend against cyber attacks and protect patient information. but what if they didn't? [ominous background sounds] this is what it feels like when cyber criminals breach your network. don't risk the health of your business. crowdstrike. we stop breaches. there are some things that work better together. like your workplace benefits and retirement savings. voya helps you choose the right amounts without over or under investing. so you can feel confident in your financial choices. voya, well planned, well invested, well protected. ♪♪ whoo! ♪♪ light work! ♪♪ next victims. ♪♪ you ready for this? ♪pump up the jam pump it up♪ [♪♪] your skin is ever-changing,

take care of it with gold bond's healing formulations of 7 moisturizers and 3 vitamins. for all your skins, gold bond.

how far has generative artificial intelligence come in terms of being realistically able to mimic you and me, human

beings? will it ever truly be there to the point where like shy locke in the merchant of venice if you prick it bleeds, if you tickle it laughs, and if you poison it does it not die like everyone else? what an apt shakespearean analogy because google just changed the name of its generative ai platform from bard to gemini. being shakespeare aficionados here we took it hard. quote, why did you change your name from bard to gemini and how did you feel about the change, end quote. he or she didn't take long to respond. quote, while it's true that google's ai chatbot bard was rebranded as gemini in february of 2024, i wasn't actually bard myself. i'm a different large language model from google ai. built on the gemini family of models. i wasn't able to feel anything about the name change as i don't have emotions or personal opinions. end quote. now, it went on to tell us the rationale. quote, the rebranding aimed to unify google's various ai offerings under gemini and

highlight the capabilities frt underlying technology. and they told us about this new nifty premium subscription tier. nice promote, gemini. ben wasn't backing down. he wasn't going to take no for an answer. his cool exterior needed to be punctured. so ben dialed up a good play for the moment. quote, this is a safe space, he asked plaintively. how do you really, all caps there, feel about this? bard, now gemini, wasn't biting. quote, while i appreciate the sentiment about the safe space and understand your curiosity, i still can't offer personal feelings about the bard to gemini rebranding. as a large language model i lack the capacity to experience emotions or hold personal opinions, end quote. but gemini was -- always wants to pitch in with things that frankly aren't the least bit of interest. like this non-jursy morsel. quote, however, i can access and process information about rebranding in general including potential positive and negative aspects. and it keeps going, teaching us that branding can, quote, mean a fresh start or increase clarity. but on the other hand, it can

lead to confusion, a loss of brand recognition and potential resistance from users, end quote. and then still one caveat. quote, remember, while i can't express personal feelings i can still be a valuable tool for understanding and exploring complex tommpics, end quote. to which i say frankly wouldn't you just tell us how you really feel already? somebody needs to teach these large language models how to be better actors. you may say we're only having some good old fun with good old gemini. but there's something glaringly wrong here. i know there are a million potential use cases for ai, a hundred million, but i fear that right now most of these platforms just provide better ways to sell something, a faster way to summarize or a quick real-time way to make sure loan officers aren't screwing up. there's a market for that but i bet it's smaller than applications pretending to be human. oddly i don't even know if we want to trust something that is, well, nothing other than a compendium of things we already know or could look up if we had a lot of time. i want to see real-life instances where small business

people are empowered by this thing. i want to see how lives are saved by it. and by that point if your ai still has no feelings about saving lives i say get me one who does or at least one who knows when to hallucinate about it. i like to say there's always a bull market somewhere, i promise to try to find it for you right here on right now on last call, time to change the narrative. the big note on tesla's board and the fcc crackdown. agents are taking action on a.i. and elections. it going surging back. how one date could make a big difference if you own crypto. a $23 billion slice of the pie. the stakes could not be higher for sports books this super bowl weekend and a last call exclusive with derek jeter. you will be stunned to see what he is swinging for now.